Fibryga

Fibryga

Manufacturer:

Octapharma

Distributor:

Pharmaniaga Marketing
Concise Prescribing Info
Contents
Human fibrinogen
Indications/Uses
Treatment of bleeding episodes & peri-op prophylaxis in patients w/ congenital hypo- or afibrinogenaemia w/ bleeding tendency. Complementary therapy in management of uncontrolled severe haemorrhage in patients w/ acquired hypofibrinogenaemia.
Dosage/Direction for Use
IV Individualised dosage. Prophylaxis in patient w/ congenital hypo- or afibrinogenaemia & known bleeding tendency 60 mg/kg at max rate: 5 mL/min. Target fibrinogen level: 1 g/L until haemostasis is secured & >0.5 g/L until wound healing is complete. Bleeding in patient w/ acquired fibrinogen deficiency Max rate: 10 mL/min. Adult Initially 1-2 g, may be increased to 4-8 g for severe hemorrhage. Paed <18 yr 20-30 mg/kg.
Contraindications
Special Precautions
Discontinue use if allergic or anaphylactic-type reactions occur. History of CHD or MI, peri- or post-op patients, patients at risk of thromboembolic events or disseminated intravascular coagulation. Carefully monitor coagulation system. Possibility of transmitting infective agents. Consider hepatitis A & B vaccination for patients in regular/repeated receipt of human plasma-derived products. Patients on controlled Na diet. Hepatic disease. Pregnancy & lactation. Neonates. Elderly ≥65 yr.
Adverse Reactions
Pyrexia, drug eruption, phlebitis, thrombosis.
MIMS Class
Haemostatics
ATC Classification
B02BB01 - fibrinogen, human ; Belongs to the class of fibrinogen. Used in the treatment of hemorrhage.
Presentation/Packing
Form
Fibryga powd for inj 1 g
Packing/Price
50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in